Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Boehringer Ingelheim
Cantor Fitzgerald
Colorcon
US Army
US Department of Justice
Healthtrust
Express Scripts

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

« Back to Dashboard

Clinical Trials for Naproxen Sodium; Sumatriptan Succinate

Trial ID Title Status Sponsor Phase Summary
NCT00329355 Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00382993 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Completed GlaxoSmithKline Phase 3 This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]
NCT00383162 A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Completed GlaxoSmithKline Phase 3 This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2]
NCT00387881 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) Completed GlaxoSmithKline Phase 3 This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Naproxen Sodium; Sumatriptan Succinate

Condition Name

Condition Name for Naproxen Sodium; Sumatriptan Succinate
Intervention Trials
Migraine Disorders 7
Migraine With or Without Aura 2
Migraine 2
Migraine Headaches 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Naproxen Sodium; Sumatriptan Succinate
Intervention Trials
Migraine Disorders 10
Premenstrual Syndrome 2
Headache 1
Dysmenorrhea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Naproxen Sodium; Sumatriptan Succinate

Trials by Country

Trials by Country for Naproxen Sodium; Sumatriptan Succinate
Location Trials
United States 138
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Naproxen Sodium; Sumatriptan Succinate
Location Trials
Tennessee 7
Texas 6
Ohio 6
North Carolina 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Naproxen Sodium; Sumatriptan Succinate

Clinical Trial Phase

Clinical Trial Phase for Naproxen Sodium; Sumatriptan Succinate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 7
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Naproxen Sodium; Sumatriptan Succinate
Clinical Trial Phase Trials
Completed 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Naproxen Sodium; Sumatriptan Succinate

Sponsor Name

Sponsor Name for Naproxen Sodium; Sumatriptan Succinate
Sponsor Trials
GlaxoSmithKline 9
Cady, Roger, M.D. 1
POZEN 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Naproxen Sodium; Sumatriptan Succinate
Sponsor Trials
Industry 10
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Julphar
Fish and Richardson
Chubb
Citi
Teva
Harvard Business School
Federal Trade Commission
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.